{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:44:25Z","timestamp":1790829865085,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T00:00:00Z","timestamp":1460764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2318-x","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T15:35:40Z","timestamp":1460820940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies"],"prefix":"10.1186","volume":"16","author":[{"given":"J\u00e9r\u00f4me","family":"Donnadieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lachaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Peria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Saidak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Dakpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fortune","family":"Ikoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Chauffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Galmiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,16]]},"reference":[{"key":"2318_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576\u201382.","journal-title":"Nature"},{"key":"2318_CR2","doi-asserted-by":"publisher","first-page":"v184","DOI":"10.1093\/annonc\/mdq185","volume":"21","author":"V Gregoire","year":"2010","unstructured":"Gregoire V, Lefebvre JL, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v184\u20136.","journal-title":"Ann Oncol"},{"key":"2318_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567\u201378.","journal-title":"N Engl J Med"},{"key":"2318_CR4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171\u20137.","journal-title":"J Clin Oncol"},{"key":"2318_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116\u201327.","journal-title":"N Engl J Med"},{"key":"2318_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/(SICI)1097-0347(199807)20:4<320::AID-HED7>3.0.CO;2-0","volume":"20","author":"LD Ke","year":"1998","unstructured":"Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck. 1998;20:320\u20137.","journal-title":"Head Neck"},{"key":"2318_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ejca.2008.11.038","volume":"45","author":"WCM Dempke","year":"2009","unstructured":"Dempke WCM, Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer. 2009;45:1117\u201328.","journal-title":"Eur J Cancer"},{"key":"2318_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cell.2012.10.014","volume":"151","author":"R Bernards","year":"2012","unstructured":"Bernards R. A missing link in genotype-directed cancer therapy. Cell. 2012;151:465\u20138.","journal-title":"Cell"},{"key":"2318_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2407-6-86","volume":"6","author":"H Kuip Van der","year":"2006","unstructured":"Van der Kuip H, M\u00fcrdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, et al. Short-term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer. 2006;6:86.","journal-title":"BMC Cancer"},{"key":"2318_CR10","doi-asserted-by":"publisher","first-page":"8352","DOI":"10.1073\/pnas.0907676107","volume":"107","author":"V Vaira","year":"2010","unstructured":"Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A. 2010;107:8352\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2318_CR11","first-page":"1415","volume":"33","author":"C Godin","year":"2013","unstructured":"Godin C, Dupont S, Ezzoukhry Z, Louandre C, Chatelain D, Henaut L, et al. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments. Anticancer Res. 2013;33:1415\u201320.","journal-title":"Anticancer Res"},{"key":"2318_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2013.700","volume":"110","author":"MM Gerlach","year":"2014","unstructured":"Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F, et al. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer. 2014;110:479\u201388.","journal-title":"Br J Cancer"},{"key":"2318_CR13","doi-asserted-by":"crossref","unstructured":"Peria M, Donnadieu J, Racz C, Ikoli JF, Galmiche A, Chauffert B, Page C. Evaluation of individual sensitivity of Head and Neck Squamous Cell Carcinoma to cetuximab by short-term culture of tumor slices. Head Neck. 2015. [Epub ahead of print].","DOI":"10.1002\/hed.24126"},{"key":"2318_CR14","volume-title":"Pathology and genetics of head and neck tumours. World Health Organization classification of tumours","author":"L Barnes","year":"2005","unstructured":"Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. World Health Organization classification of tumours. Geneva: WHO Press; 2005."},{"key":"2318_CR15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046\u201351.","journal-title":"Nat Biotechnol"},{"key":"2318_CR16","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","volume":"9","author":"N Munshi","year":"2010","unstructured":"Munshi N, Jeay S, Li Y, Chen CR, France DS, Hill J, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010;9:1544\u201353.","journal-title":"Mol Cancer Ther"},{"key":"2318_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","volume":"11","author":"JM Gozgit","year":"2012","unstructured":"Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther. 2012;11:690\u20139.","journal-title":"Mol Cancer Ther"},{"key":"2318_CR18","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1002\/ijc.29344","volume":"136","author":"K Klinghammer","year":"2015","unstructured":"Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, et al. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option. Int J Cancer. 2015;136:2940\u20138.","journal-title":"Int J Cancer"},{"key":"2318_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1586\/erm.10.120","volume":"11","author":"M Buyse","year":"2011","unstructured":"Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn. 2011;11:171\u201382.","journal-title":"Expert Rev Mol Diagn"},{"key":"2318_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160:977\u201389.","journal-title":"Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2318-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2318-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T15:45:50Z","timestamp":1567784750000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2318-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,16]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2318"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2318-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,16]]},"article-number":"273"}}